Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clostridium Butyricum might be an effective drug in treating irritable bowel syndrome

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients

NCT02254629

Irritable Bowel Syndrome

COMPLETED PHASE1

Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients

NCT03359499

Irritable Bowel Syndrome

COMPLETED PHASE2/PHASE3

The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome

NCT02108119

Irritable Bowel Syndrome

COMPLETED PHASE2

Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia

NCT07182890

Functional Dyspepsia Probiotics Depression +1 more

RECRUITING PHASE4

B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis

NCT06612411

Irritable Bowel Syndrome with Diarrhea Purine Metabolism Disorder

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clostridium Butyricum group

Irritable bowel syndrome patients treated with Clostridium Butyricum

Group Type EXPERIMENTAL

Clostridium Butyricum

Intervention Type DRUG

Irritable bowel syndrome patients treated with Clostridium Butyricum

Placebo group

Irritable bowel syndrome patients treated with placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Irritable bowel syndrome patients treated with placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clostridium Butyricum

Irritable bowel syndrome patients treated with Clostridium Butyricum

Intervention Type DRUG

placebo

Irritable bowel syndrome patients treated with placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* the presence of Rome III criteria for IBS ;
* Aged between 18 and 65 years old

Exclusion Criteria

* Antibiotic, probiotic or laxative usage within 4 weeks.
* organic gastrointestinal diseases
* Severe systematic disease: diabetes mellitus, hepatic, renal or cardiac dysfunction, thyroid disease or tumor etc.
* pregnancy or lactation.
* previous major or complicated abdominal surgery.
* severe endometriosis and dementia

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No